CA3297636A1 - Formulations stabilisées contenant des anticorps bispécifiques anti-bcma x anti-cd3 - Google Patents

Formulations stabilisées contenant des anticorps bispécifiques anti-bcma x anti-cd3

Info

Publication number
CA3297636A1
CA3297636A1 CA3297636A CA3297636A CA3297636A1 CA 3297636 A1 CA3297636 A1 CA 3297636A1 CA 3297636 A CA3297636 A CA 3297636A CA 3297636 A CA3297636 A CA 3297636A CA 3297636 A1 CA3297636 A1 CA 3297636A1
Authority
CA
Canada
Prior art keywords
bcma
bispecific antibodies
formulations containing
stabilized formulations
containing anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3297636A
Other languages
English (en)
Inventor
Kenneth S. Graham
Saurabh Wadhwa
Douglas Kamen
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3297636A1 publication Critical patent/CA3297636A1/fr
Pending legal-status Critical Current

Links

CA3297636A 2023-07-07 2024-07-05 Formulations stabilisées contenant des anticorps bispécifiques anti-bcma x anti-cd3 Pending CA3297636A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63/525,652 2023-07-07
US63/613,540 2023-12-21

Publications (1)

Publication Number Publication Date
CA3297636A1 true CA3297636A1 (fr) 2025-01-16

Family

ID=

Similar Documents

Publication Publication Date Title
IL307879A (en) High concentration bispecific antibody formulations
EP4303231A4 (fr) Anticorps bispécifique
EP4171661A4 (fr) Compositions de dota-haptène pour radioimmunothérapie préciblée à anticorps bispécifique anti-antigène tumoral/anti-dota
CA3261147A1 (fr) Dosage pour traitement avec anticorps bispécifiques anti-fcrh5/anti-cd3
IL306042A (en) Stabilized formulations include bispecific antibodies against MUC16 and CD3
CA3297636A1 (fr) Formulations stabilisées contenant des anticorps bispécifiques anti-bcma x anti-cd3
CA3260186A1 (fr) Formulations pour anticorps bispécifiques anti-pd-l1/anti-4-1bb
HK40106470A (en) Stabilized formulations containing anti-muc16 x anti-cd3 bispecific antibodies
IL325692A (en) Stabilized formulations including bispecific antibodies against BCMA and CD3
HK40082040A (en) Stabilized formulations containing anti-cd20 x anti-cd3 bispecific antibodies
IL299152A (en) Stabilized formulations that include antibodies against CTLA-4
HK40119561A (en) Formulations for anti-pd-l1/anti-4-1bb bispecific antibodies
CA3271834A1 (fr) Anticorps anti-cd3
HK40130655A (zh) 抗cd3抗体
HK40107773A (en) High concentration bispecific antibody formulations
HK40127140A (en) Pharmaceutical composition comprising anti-rankl-ngf bispecific antibodies
CA3272308A1 (fr) Composition pharmaceutique comprenant des anticorps bispécifiques anti-rankl-ngf
HK40093977A (en) Stabilized formulations containing anti-ctla-4 antibodies
HK40121386A (en) Stable formulations for antibodies
CA3288182A1 (fr) Anticorps bispécifiques à charnière modifiée
CA3283846A1 (fr) Anticorps bispécifiques agonistes de 4-1bb dépendant de ceacam5
CA3270337A1 (fr) Composés d'anticorps bispécifiques
CA3269753A1 (fr) Formulations pour anticorps anti-c1q
HK40115753A (en) Stable formulations comprising a bispecific bcma/cd3 antibody
CA3275925A1 (fr) Formulations d'anticorps anti-pd1